BioCryst Pharmaceuticals Acquires Presidio Pharmaceuticals for $101,000,000

  • Feed Type
  • Date
    10/19/2012
  • Company Name
    Presidio Pharmaceuticals
  • Mailing Address
    1700 Owens Street San Francisco, CA 94158
  • Company Description
    Presidio is focused on developing novel and established therapeutic modalities and small molecule compounds for the treatment of HIV-1, HCV and other chronic virus infections.
  • Website
    http://www.presidiopharma.com
  • Transaction Type
    M&A
  • Transaction Amount
    $101,000,000
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    The acquisition will be paid for with all stock.

By posting a comment, you agree to our terms and conditions.